Histomorphological Evaluation of Desmoplastic Tumor Stroma in Malignant Ovarian Surface Epithelial Tumors

Overview

Journal J Midlife Health

Date 2023 Nov 29

PMID 38029034

Authors

Sana Ahuja

Sufian Zaheer

Sunil Ranga

Affiliations

Soon will be listed here.

Abstract

Background: Ovarian cancer is the 8 most common cancer in women worldwide. Tumor budding is defined as a type of invasive growth in carcinomas with either a single tumor cell or a cluster of up to four cells at the invasive tumor front and is associated with epithelial-mesenchymal transition. A reactive stroma rich in cancer-associated fibroblasts is associated with higher tumor grade and poorer prognosis in breast, colorectal, and oral cancers.

Aims And Objectives: The present study was conducted to highlight the prognostic significance of tumor budding and fibrotic cancer stroma in malignant ovarian surface epithelial tumors with known prognostic parameters.

Materials And Methods: This was a retrospective cross-sectional study conducted over a 2-year period, in which all histologically diagnosed cases of malignant ovarian surface epithelial tumors who underwent surgery were included. The fibrotic stroma was classified into three distinct categories - mature, intermediate, and immature. The number of tumor buds was counted at the invasive front of the tumor and graded based on the number of buds - 0-5, 5-9, and ≥10 buds.

Results: Among the 50 cases, 32% (16 cases) had mature stroma, whereas 30% (15 cases) and 38% (19 cases) had intermediate and immature stroma, respectively. Although a significant association could not be established between tumor budding and stroma grade, a fair agreement was established between them. A significant association could be established between histological grade with both tumor budding ( = 0.03) and fibrotic stroma grade ( = 0.02).

Conclusion: The study highlighted the role of stromal response in malignant surface epithelial tumors of the ovary since a higher-grade tumor was associated with an immature stroma, whereas a lower-grade tumor was associated with a mature stroma.

References

Gonzalez-Guerrero M, Martinez-Camblor P, Vivanco B, Fernandez-Vega I, Munguia-Calzada P, Gonzalez-Gutierrez M . The adverse prognostic effect of tumor budding on the evolution of cutaneous head and neck squamous cell carcinoma. J Am Acad Dermatol. 2017; 76(6):1139-1145. DOI: 10.1016/j.jaad.2017.01.015. View

Schoppmann S, Berghoff A, Dinhof C, Jakesz R, Gnant M, Dubsky P . Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. Breast Cancer Res Treat. 2012; 134(1):237-44. DOI: 10.1007/s10549-012-1984-x. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Joyce J, Pollard J . Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009; 9(4):239-52. PMC: 3251309. DOI: 10.1038/nrc2618. View

Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H . Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017; 30(9):1299-1311. DOI: 10.1038/modpathol.2017.46. View

Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H . Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019; 11:287-299. PMC: 6500433. DOI: 10.2147/IJWH.S197604. View

Hase K, Shatney C, Johnson D, Trollope M, Vierra M . Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum. 1993; 36(7):627-35. DOI: 10.1007/BF02238588. View

Ueno H, Mochizuki H, Hatsuse K, Hase K, Yamamoto T . Indicators for treatment strategies of colorectal liver metastases. Ann Surg. 2000; 231(1):59-66. PMC: 1420966. DOI: 10.1097/00000658-200001000-00009. View

Otranto M, Sarrazy V, Bonte F, Hinz B, Gabbiani G, Desmouliere A . The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr. 2012; 6(3):203-19. PMC: 3427235. DOI: 10.4161/cam.20377. View

10.

Mitrovic B, Schaeffer D, Riddell R, Kirsch R . Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol. 2012; 25(10):1315-25. DOI: 10.1038/modpathol.2012.94. View

11.

van Wyk H, Roseweir A, Alexander P, Park J, Horgan P, McMillan D . The Relationship Between Tumor Budding, Tumor Microenvironment, and Survival in Patients with Primary Operable Colorectal Cancer. Ann Surg Oncol. 2019; 26(13):4397-4404. PMC: 6863941. DOI: 10.1245/s10434-019-07931-6. View

12.

Chen Y, Zhang L, Liu W, Liu X . Prognostic Significance of the Tumor-Stroma Ratio in Epithelial Ovarian Cancer. Biomed Res Int. 2015; 2015:589301. PMC: 4644548. DOI: 10.1155/2015/589301. View

13.

Herrera M, Herrera A, Dominguez G, Silva J, Garcia V, Garcia J . Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci. 2013; 104(4):437-44. PMC: 7657228. DOI: 10.1111/cas.12096. View

14.

Ueno H, Jones A, Wilkinson K, Jass J, Talbot I . Histological categorisation of fibrotic cancer stroma in advanced rectal cancer. Gut. 2004; 53(4):581-6. PMC: 1774016. DOI: 10.1136/gut.2003.028365. View

15.

Lugli A, Zlobec I, Berger M, Kirsch R, Nagtegaal I . Tumour budding in solid cancers. Nat Rev Clin Oncol. 2020; 18(2):101-115. DOI: 10.1038/s41571-020-0422-y. View

16.

Peltanova B, Raudenska M, Masarik M . Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review. Mol Cancer. 2019; 18(1):63. PMC: 6441173. DOI: 10.1186/s12943-019-0983-5. View

17.

Zlobec I, Lugli A . Tumour budding in colorectal cancer: molecular rationale for clinical translation. Nat Rev Cancer. 2018; 18(4):203-204. DOI: 10.1038/nrc.2018.1. View

18.

Tsujino T, Seshimo I, Yamamoto H, Ngan C, Ezumi K, Takemasa I . Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res. 2007; 13(7):2082-90. DOI: 10.1158/1078-0432.CCR-06-2191. View

19.

Ueno H, Murphy J, Jass J, Mochizuki H, Talbot I . Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002; 40(2):127-32. DOI: 10.1046/j.1365-2559.2002.01324.x. View